AbbVie Announces Largest-Ever Capital Investment in Single Campus as Part of $100 Billion U.S. R&D Commitment

On April 22, 2026, AbbVie announced a $1.4 billion investment to construct a new pharmaceutical manufacturing campus in Durham, North Carolina, marking its largest-ever capital investment in a single site since the company’s inception.

The 185-acre facility will focus on the production of AbbVie’s immunology, neuroscience and oncology medicines, integrating advanced manufacturing and laboratory technologies with artificial intelligence to support operations.

This investment represents AbbVie’s first major commitment to North Carolina and demonstrates continued progress toward its $100 billion pledge to U.S. Research and development and capital investments, including manufacturing, over the next decade.

Construction is set to begin in 2026, with completion expected by the end of 2028. Upon full operation, the campus is projected to create 734 new jobs, including positions for engineers, scientists, manufacturing operators and laboratory technicians.

AbbVie selected the Durham location due to the strength of the region’s local workforce and its proximity to Research Triangle Park, which the company noted supports its ability to plan for future expansion.

According to Robert A. Michael, chairman and chief executive officer of AbbVie, the investment is a significant milestone for the company as it expands its manufacturing footprint into a new region of the United States.

By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.

Robert A. Michael, Chairman and CEO, AbbVie

The AbbVie Durham campus will be located near Research Triangle Park, a region recognized for its concentration of life sciences and technology employers.

This development follows AbbVie’s broader strategy to increase domestic manufacturing capacity as part of its long-term commitment to U.S.-based research, development and production capabilities.